behc
diseas
bd
chronic
system
inflammatori
diseas
unclear
etiopathogenesi
although
gene
variant
cc
chemokin
receptor
type
report
protein
express
patient
bd
remain
unclear
object
studi
analyz
frequenc
cell
herp
simplex
virusinduc
mous
model
bd
frequenc
cell
surfac
cytoplasm
peripher
blood
mononuclear
cell
lymph
node
analyz
flow
cytometri
cell
significantli
downregul
bd
mice
compar
normal
control
symptomfre
control
mice
colchicin
pentoxifyllin
treatment
improv
symptom
bd
increas
frequenc
cell
bd
mice
treatment
chemokin
cc
motif
ligand
ligand
caus
bd
symptom
deterior
bd
mice
via
downregul
cell
antibodi
treatment
amelior
bd
symptom
mice
significantli
decreas
diseas
sever
score
compar
bd
mice
p
via
upregul
cell
frequenc
patient
bd
plasma
level
activ
state
significantli
higher
healthi
control
individu
p
result
show
upregul
cell
relat
control
system
inflamm
bd
mous
model
behc
diseas
bd
chronic
system
inflammatori
diseas
unclear
etiopathogenesi
gene
variant
cc
chemokin
receptor
type
patient
bd
identifi
genomewid
associ
studi
howev
protein
express
patient
bd
mous
model
remain
unclear
cc
chemokin
receptor
type
express
cell
immun
system
includ
lymphocyt
monocyt
neutrophil
dendrit
cell
involv
host
defens
hematopoiesi
helper
type
cell
balanc
chemotaxi
express
correl
variou
inflammatori
diseas
includ
rheumatoid
arthriti
asthma
lupu
nephriti
knockout
mice
show
reduc
pulmonari
inflamm
prolong
allograft
surviv
polymorph
might
gener
risk
factor
autoimmun
inflammatori
diseas
antagonist
use
clinic
trial
treat
multipl
sclerosi
psoriasi
rheumatoid
arthriti
herp
simplex
viru
hsv
report
etiolog
factor
bd
mous
model
hsvinduc
inflammatori
bd
develop
use
variou
studi
object
present
studi
determin
express
mice
inflammatori
bd
symptom
investig
whether
regul
ligand
agonist
antagonist
flow
abbrevi
bd
behc
diseas
bdn
herp
simplex
virusinocul
asymptomat
healthi
mice
chemokin
cc
motif
ligand
cc
chemokin
receptor
type
gmcsf
granulocytemacrophag
colonystimul
factor
male
icr
mice
week
old
infect
hsv
type
plaqueform
unitsml
f
strain
grown
vero
cell
describ
previous
viru
inocul
twice
mice
frequenc
day
second
hsv
inocul
mice
observ
week
week
anim
handl
accord
guidelin
provid
institut
anim
care
use
committe
ajou
univers
school
medicin
among
mice
infect
hsv
develop
bdlike
symptom
includ
skin
ulcer
skin
pustul
genit
ulcer
erythema
oral
ulcer
ear
inflamm
arthriti
genit
ulcer
red
eye
left
right
reduc
vision
left
right
weight
loss
facial
swell
oral
genit
skin
ulcer
eye
symptom
classifi
major
symptom
symptom
identifi
minor
symptom
mice
display
one
major
one
minor
symptom
diagnos
bd
symptom
score
assign
singl
point
sum
symptom
score
use
determin
sever
bd
disappear
symptom
decreas
lesion
size
classifi
symptom
improv
diseas
sever
score
bd
calcul
accord
bd
activ
index
outlin
bd
activ
form
wwwbehcetw
pdfbehcetsdiseaseactivityformpdf
hsvinocul
asymptomat
healthi
mice
bdn
mice
serv
control
group
describ
previous
peripher
blood
mononuclear
cell
ln
cell
isol
mice
erythrocyt
elimin
ammoniumchloridepotassium
solut
wash
phosphatebuff
salin
pb
follow
surfac
stain
cell
mous
allophycocyaninconjug
antibodi
cat
r
system
minneapoli
mn
min
dark
intracytoplasm
stain
cell
fix
intracytoplasm
fixat
buffer
min
room
temperatur
wash
twice
permeabil
buffer
cell
stain
antimous
antibodi
follow
analysi
cell
flow
cytomet
fac
canto
ii
becton
dickinson
san
jose
ca
fresh
pbmc
wash
twice
cold
pb
lyze
lysi
buffer
mm
triscl
ph
nacl
mm
edta
triton
lgml
aprotinin
leupeptin
mm
phenylmethylsulphonyl
fluorid
protein
lg
lysat
electrophores
sodium
dodecyl
sulfatepolyacrylamid
gel
protein
transfer
onto
nitrocellulos
membran
protran
ge
healthcar
life
scienc
chicago
il
usa
subject
immunoblot
analysi
use
antibodi
immunoblot
develop
enhanc
chemiluminesc
system
ge
healthcar
life
scienc
antibodi
purchas
r
system
glyceraldehyd
dehydrogenas
gapdh
antibodi
santa
cruz
biotechnolog
inc
dalla
tx
normal
bd
mice
treat
vivo
pb
pgmouseday
cat
prospecbio
nessziona
israel
granulocytemacrophag
colonystimul
factor
gmcsf
pgmouseday
cat
prospecbio
chemokin
cc
motif
ligand
pgmouseday
cat
prospecbio
antibodi
ngmouseday
cat
r
system
five
consecut
day
intraperiton
administr
normal
mice
week
old
pbmc
ln
cell
isol
hr
last
medic
analysi
cell
flow
cytometri
antagonist
cat
sigmaaldrich
st
loui
mo
intraperiton
administ
normal
bd
mice
mg
mous
three
time
everi
day
bd
symptom
observ
treatment
imag
obtain
document
treatmentrel
chang
mice
treat
oral
pb
colchicin
lgmous
day
pentoxifyllin
lgmouseday
five
consecut
day
chang
symptom
monitor
hr
last
medic
mice
kill
intramuscular
inject
hind
leg
ketaminexylazin
cocktail
mgkg
ketamin
mgkg
xylazin
pbmc
ln
cell
isol
analysi
cell
depart
dermatolog
ajou
univers
hospit
sampl
patient
bd
random
patient
first
arriv
clinic
characterist
therapeut
histori
patient
shown
tabl
accord
intern
studi
group
bd
criteria
presenc
two
follow
symptom
addit
recurr
oral
ulcer
consid
bd
diagnosi
recurr
genit
ulcer
cutan
erythema
nodosum
largevessel
vascul
arthriti
uveiti
andor
posit
pathergi
test
diseas
sever
score
calcul
behc
diseas
current
activ
form
http
wwwbehcetdiseasesocietyorgbehcetwsdataupload
filesbehcetsdiseaseactivityformpdf
patient
activ
bd
n
men
one
woman
ae
year
enrol
gender
differ
among
bd
patient
mucocutan
manifest
inconsist
among
differ
nation
inform
consent
obtain
patient
studi
healthi
control
group
n
ae
year
compris
one
man
women
serum
provid
biobank
ajou
univers
hospit
member
korea
biobank
network
studi
approv
ethic
committe
ajou
univers
medic
center
institut
review
board
experi
conduct
accord
institut
review
board
permit
protocol
peripher
blood
collect
edtaco
test
tube
centrifug
g
min
supernat
store
use
level
measur
plasma
use
commerci
enzymelink
immunosorb
assay
elisa
kit
cat
thermo
fisher
scientif
waltham
follow
manufactur
instruct
elisa
analysi
sampl
appli
duplic
well
three
time
differ
elisa
plate
data
statist
analysi
compli
recommend
experiment
design
analysi
pharmacolog
flow
cytometr
analysi
perform
analyz
surfac
cytoplasm
cell
stain
antibodi
pbmc
ln
cell
isol
normal
n
bdn
n
bd
n
mice
frequenc
cell
surfac
pbmc
significantli
downregul
bd
mice
compar
normal
mice
ae
versu
ae
p
bdn
mice
ae
versu
ae
p
frequenc
cell
surfac
ln
cell
also
downregul
bd
mice
compar
normal
mice
ae
versu
ae
p
bdn
mice
ae
versu
ae
p
fig
frequenc
cytoplasm
stain
pbmc
significantli
lower
bd
mice
normal
mice
ae
versu
ae
p
bdn
mice
ae
versu
ae
p
frequenc
ln
cell
also
significantli
lower
bd
mice
normal
mice
ae
versu
ae
p
differ
frequenc
cell
bd
bdn
mice
ae
versu
ae
p
fig
repres
histogram
surfac
stain
result
present
fig
c
figur
show
western
blot
analysi
express
whole
pbmc
lysat
normal
bdn
bd
mice
n
group
express
ratio
compar
gapdh
differ
bdn
ae
bd
ae
mice
fig
n
mean
entir
amount
pbmc
correl
symptom
synergist
enhanc
gmcsfinduc
gmcsf
known
cytokin
therefor
gmcsf
administ
normal
bd
mice
determin
function
dose
mice
vivo
gmcsf
inject
normal
mice
intraperiton
follow
dose
pg
gmcsf
pg
hr
last
treatment
pbmc
isol
mice
flow
cytometri
measur
frequenc
cell
surfac
cytoplasm
mice
treat
pg
n
frequenc
surfac
cell
significantli
upregul
pbmc
compar
pbstreat
control
mice
n
ae
versu
ae
p
treatment
pg
n
affect
frequenc
cell
compar
pbstreat
control
mice
n
ae
versu
ae
p
treatment
pg
n
upregul
frequenc
cell
compar
pbstreat
control
mice
n
although
differ
statist
signific
ae
versu
ae
p
frequenc
cytoplasm
pbmc
slightli
increas
mice
treat
pg
pg
compar
pbstreat
control
mice
ae
versu
ae
p
ae
versu
ae
p
although
differ
statist
signific
fig
normal
mice
expos
pg
gmcsf
n
frequenc
surfac
pbmc
upregul
compar
pbstreat
control
mice
ae
versu
ae
p
mice
treat
pg
gmcsf
n
frequenc
cell
higher
compar
level
pbstreat
control
mice
n
ae
versu
ae
p
howev
differ
statist
signific
mice
treat
pg
gmcsf
n
show
frequenc
cell
similar
pbstreat
control
mice
n
cytoplasm
pbmc
frequenc
cell
mice
treat
gmcsf
pg
ae
ae
ae
respect
significantli
p
differ
compar
pb
control
group
ae
fig
gmcsf
upregul
frequenc
cell
bd
mice
accord
function
dose
gmcsf
normal
mice
pgmouseday
pg
mouseday
gmcsf
administ
bd
mice
upregul
cell
five
consecut
day
treatment
bd
mice
pbmc
ln
cell
subject
surfac
cytoplasm
stain
fac
analysi
surfac
pbmc
frequenc
cell
bd
mice
treat
n
gmcsf
n
show
signific
upregul
compar
pbstreat
bd
mice
n
versu
pb
ae
versu
ae
p
gmcsf
versu
pb
ae
versu
ae
p
surfac
ln
cell
significantli
upregul
compar
pbstreat
bd
mice
versu
pb
ae
versu
ae
p
gmcsf
versu
pb
ae
versu
ae
p
fig
cytoplasm
pbmc
also
increas
treatment
ae
versu
ae
p
gmcsf
ae
versu
ae
p
compar
pbstreat
bd
mice
cytoplasm
cell
ln
increas
gmcsf
ae
versu
p
frequenc
cytoplasm
ln
cell
chang
treatment
fig
gmcsf
upregul
frequenc
cell
normal
bd
mice
downregul
express
cell
normal
mice
multipl
ligand
one
ligand
downregul
function
determin
whether
regul
intraperiton
inject
normal
mice
frequenc
pbmc
ln
cell
decreas
treatment
surfac
stain
pbmc
treatment
pg
n
significantli
decreas
frequenc
cell
compar
pb
control
n
ae
versu
ae
p
treatment
pg
decreas
frequenc
cell
although
decreas
signific
ae
versu
ae
p
surfac
stain
ln
cell
treatment
pg
n
significantli
downregul
frequenc
cell
compar
pb
control
n
ae
versu
ae
p
treatment
pg
n
result
similar
frequenc
cell
compar
pbstreat
control
mice
fig
frequenc
cytoplasm
pbmc
treatment
pg
significantli
decreas
ae
p
ae
p
compar
pb
control
ae
cytoplasm
ln
cell
significantli
downregul
mice
treat
pg
ae
p
pg
ae
p
compar
pbstreat
control
mice
ae
fig
histogram
surfac
cytoplasm
pbmc
treatment
present
fig
c
downregul
cell
bd
mice
pg
day
administ
bd
mice
n
five
consecut
day
frequenc
surfac
pbmc
significantli
lower
compar
pbstreat
bd
mice
n
ae
versu
ae
p
frequenc
surfac
ln
cell
differ
treatment
fig
cytoplasm
ln
cell
downregul
significantli
treatment
compar
pb
control
ae
versu
ae
p
howev
express
chang
pbmc
cytoplasm
fig
treatment
deterior
bd
symptom
bd
mice
diseas
sever
score
increas
ae
ae
day
treatment
four
bd
mice
show
new
skin
ulcer
arthriti
remain
bd
mice
show
increas
ulcer
size
antagonist
downregul
cell
bd
mice
develop
antagonist
treat
sever
inflammatori
diseas
includ
rheumatoid
arthriti
administ
bd
mice
downregul
bd
mice
n
show
ae
surfac
pbmc
ae
surfac
ln
cell
ae
cytoplasm
pbmc
ae
cytoplasm
ln
cell
bd
mice
play
role
downregul
cell
fig
b
normal
mice
mice
show
higher
frequenc
surfac
pbmc
pbstreat
normal
mice
ae
versu
ae
p
ln
cell
ae
versu
ae
p
inhibit
express
found
cytoplasm
pbmc
versu
pb
ae
versu
ae
p
fig
colchicin
pentoxifyllin
frequent
prescrib
medic
bd
also
use
bd
mice
determin
correl
express
two
agent
colchicin
n
pentoxifyllin
n
administ
normal
mice
surfac
express
pbmc
significantli
upregul
compar
pbstreat
normal
mice
n
colchicin
versu
pb
ae
versu
ae
p
pentoxifyllin
versu
pb
ae
versu
ae
p
colchicin
significantli
upregul
express
surfac
ln
cell
compar
pbstreat
normal
mice
ae
versu
ae
p
pentoxifyllin
also
upregul
express
compar
pbstreat
normal
mice
although
upregul
statist
signific
ae
versu
ae
p
fig
colchicin
pentoxifyllin
significantli
downregul
express
cytoplasm
pbmc
ae
p
ae
p
respect
compar
pb
control
ae
cytoplasm
express
ln
cell
alter
colchicin
pentoxifyllin
treatment
fig
frequenc
cell
determin
bd
mice
treat
medic
treatment
colchicin
n
pentoxifyllin
n
significantli
upregul
surfac
express
pbmc
bd
mice
compar
pbstreat
bd
mice
n
ae
versu
ae
p
ae
versu
ae
p
respect
frequenc
surfac
ln
cell
also
increas
significantli
colchicin
pentoxifyllin
compar
pbstreat
bd
mice
ae
versu
ae
p
ae
versu
ae
p
respect
fig
cytoplasm
pbmc
treatment
colchicin
pentoxifyllin
increas
frequenc
cell
howev
pentoxifyllin
treatment
result
signific
increas
ae
versu
ae
p
colchicin
pentoxifyllin
affect
frequenc
cytoplasm
ln
cell
compar
pbstreat
bd
mice
fig
histogram
express
surfac
cytoplasm
pbmc
treatment
colchicin
pentoxifyllin
present
fig
e
result
show
frequenc
surfac
express
rather
cytoplasm
express
strongli
correl
regul
bd
symptom
determin
whether
regul
inhibit
antibodi
intraperiton
inject
normal
mice
frequenc
pbmc
ln
cell
increas
antibodi
treatment
surfac
stain
pbmc
treatment
antibodi
ng
significantli
increas
frequenc
cell
compar
pbstreat
normal
mice
ng
ae
p
ng
ae
p
ng
ae
p
ng
ae
p
ng
ae
p
versu
pb
ae
surfac
stain
ln
cell
treatment
antibodi
significantli
upregul
frequenc
ln
cell
compar
pbstreat
normal
mice
ng
ae
p
ng
ae
p
ng
ae
p
ng
ae
p
ng
ae
p
versu
pb
ae
fig
cytoplasm
frequenc
pbmc
treatment
antibodi
ng
alter
significantli
pbmc
cytoplasm
compar
pbstreat
normal
mice
ng
ae
ng
ae
ng
ae
ng
ae
ng
ae
versu
pb
ae
fig
cytoplasm
ln
cell
significantli
upregul
mice
treat
ng
antibodi
ae
p
ng
antibodi
ae
p
compar
pbstreat
normal
mice
ae
treatment
ng
yield
signific
chang
compar
pbstreat
normal
mice
fig
upregul
cell
bd
mice
antibodi
ngday
administ
bd
mice
n
five
consecut
day
frequenc
express
surfac
pbmc
significantli
increas
compar
pbstreat
bd
mice
n
ae
versu
ae
p
ln
cell
frequenc
surfac
express
significantli
increas
antibodi
treatment
ae
versu
ae
p
fig
cytoplasm
pbmc
frequenc
express
treatment
antibodi
upregul
significantli
compar
pb
control
ae
versu
ae
p
howev
cytoplasm
ln
cell
downregul
treatment
antibodi
compar
pb
control
ae
versu
ae
p
fig
antibodi
treatment
improv
bd
symptom
bd
mice
day
initi
antibodi
treatment
list
improv
mice
provid
supplementari
materi
tabl
diseas
sever
score
bd
mice
chang
ae
ae
day
symptom
improv
antibodi
treatment
p
diseas
sever
score
also
significantli
vari
bd
mice
ae
antibodytr
bd
mice
ae
day
five
p
fig
figur
show
chang
symptom
treatment
antibodi
bd
mice
level
patient
activ
bd
ae
pgml
higher
patient
inact
bd
ae
pgml
p
healthi
control
individu
ae
pgml
p
fig
studi
quantit
analyz
express
chemokin
receptor
pbmc
ln
cell
bd
mice
result
suggest
bdlike
symptom
correl
frequenc
cell
percentag
cell
significantli
downregul
bd
mice
compar
normal
bdn
mice
cytokin
gmcsftreat
bd
mice
exhibit
signific
upregul
cell
compar
pbstreat
bd
mice
ligand
bd
mice
show
signific
downregul
cell
compar
pb
treat
bd
mice
ten
bd
mice
show
deterior
bd
symptom
antibodi
treatment
improv
bd
symptom
decreas
diseas
sever
score
upregul
cell
significantli
compar
pbstreat
bd
mice
treatment
bd
mice
colchicin
pentoxifyllin
significantli
upregul
cell
compar
pb
treatment
frequenc
cell
strongli
associ
symptom
bd
mice
chemokin
receptor
essenti
moder
leukocyt
traffick
inflammatori
diseas
may
strong
therapeut
target
varieti
diseas
shown
play
role
recruit
monocyt
cell
accord
activ
inflamm
ligand
associ
develop
experiment
arthriti
rheumatoid
arthriti
effici
therapeut
target
mediat
regul
tumor
necrosi
factora
howev
patient
bd
frequenc
cell
decreas
patient
activ
bd
normal
control
even
though
differ
statist
signific
similarli
studi
also
show
frequenc
cell
bd
mice
downregul
compar
control
mice
downregul
express
report
infect
leishmania
infantum
coronaviru
correl
hsv
infect
express
show
consist
result
chemokin
express
report
arthrit
inflamm
recruit
inflammatori
leukocyt
bind
affect
chronic
joint
inflamm
neutral
antibodi
allevi
inflamm
higher
serum
level
found
patient
activ
bd
patient
inact
stage
bd
result
present
studi
demonstr
treatment
deterior
symptom
bd
mice
downregul
frequenc
cell
increas
express
exacerb
bd
symptom
downregul
known
stimul
mainli
express
monocyt
macrophag
cell
b
cell
one
key
antiinflammatori
cytokin
express
human
immun
respons
strong
inhibitor
cytokin
interferonc
antiinflammatori
cytokin
suppress
proinflammatori
cytokin
protect
host
tissu
damag
patient
bd
polymorph
identifi
gene
variat
might
correl
insuffici
express
result
present
studi
show
upregul
frequenc
cell
bd
mice
compar
pb
control
gmcsf
also
synergist
increas
frequenc
cell
bd
mice
granulocytemacrophag
colonystimul
factor
stimul
express
enhanc
matur
dendrit
cell
play
role
recruit
circul
neutrophil
monocyt
lymphocyt
host
defens
differ
type
inflammatori
immun
cell
dendrit
cell
monocyt
neutrophil
microglia
macrophag
modul
gmcsf
autoimmun
condit
gmcsf
may
influenc
chronic
inflammatori
diseas
arthriti
experiment
autoimmun
enceph
airway
inflamm
gmcsf
also
enhanc
resist
viral
infect
bacteri
transloc
patient
bd
gmcsf
transcript
downregul
control
howev
protein
express
serum
level
gmcsf
patient
bd
yet
elucid
accord
case
report
intralesion
inject
recombin
human
gmcsf
induc
wound
heal
genit
ulcer
bd
gmcsf
also
enhanc
express
data
demonstr
treatment
gmcsf
significantli
upregul
express
pbmc
ln
cell
develop
potent
antagonist
treatment
attenu
system
inflamm
sepsi
nephriti
arthriti
myocard
studi
administ
bd
mice
confirm
correl
express
bd
inhibit
treatment
fail
inhibit
frequenc
surfac
cytoplasm
pbmc
ln
cell
bd
mice
normal
mice
inhibit
express
cytoplasm
pbmc
result
indic
treatment
fail
adequ
inhibit
cell
vivo
partli
explain
clinic
trial
inhibit
discontinu
conclus
studi
demonstr
downregul
frequenc
cell
close
correl
bd
symptom
express
cell
control
cytokin
gmcsf
ligand
even
though
bd
multifactori
inflammatori
diseas
associ
immun
dysregul
treatment
singl
chemokin
chemokin
receptor
alon
contribut
immun
regul
result
control
system
symptom
bd
